Skip to main content

Studies on the effects of heparin products on pregnancy-associated plasma protein A.

Wittfooth S, Tertti R, Lepäntalo M, Porela P, Qin QP, Tynjälä J, Inkinen O, Perttilä J, Airaksinen KE, Pettersson K

Publication: Clin Chim Acta (2011) • Vol 412 • Page 376-81PMID: 21094153View on PubMed

Purpose

The purpose of this paper was to determine the effects of intravenous and subcutaneous administration of anticoagulants on pregnancy-associated plasma protein A (PAPP-A) in serum specimens.

Conclusion

Intravenous administration of low molecular weight heparin (LMWH) or unfractionated heparin (UFH) resulted in a significant increase in free PAPP-A levels in serum specimens, which then cleared rapidly. Subcutaneous administration of LMWH also resulted in a smaller and slower increase in free PAPP-A levels in serum than that observed with intravenous anticoagulant administration. Intravenous bivalirudin and gender had no effects on free PAPP-A. Complexed PAPP-A levels were unaffected by anticoagulants. Free PAPP-A was found to have a larger molecular size in the presence of heparin.

Studies (1)

Purpose

The purpose of this study was to determine the effects of intravenous and subcutaneous administration of anticoagulants on PAPP-A levels in serum specimens. All specimens were stored at -70 degrees C until analysis.

Summary of Findings

Intravenous administration of LMWH or UFH resulted in a rapid increase in free PAPP-A levels in serum specimens taken 5 or 10 minutes after administration of the anticoagulant, 85% of which was then cleared with a half-life of 13.1 minutes. Subcutaneous administration of LMWH also resulted in a smaller and slower increase in free PAPP-A levels in serum than that observed with intravenous anticoagulant administration. Intravenous bivalirudin and gender had no effects on free PAPP-A. Complexed PAPP-A levels were unaffected by anticoagulants. In acute coronary syndrome patients, the molecular size of free PAPP-A was larger in heparin plasma than in serum. Free PAPP-A extracted from a plaque tissue specimen with LMWH was also found to have a larger molecular size than PAPP-A extracted with sodium chloride. Further, recombinant PAPP-A diluted in serum with LMWH or in heparin plasma had a larger molecular size than recombinant PAPP-A in serum with no LMWH.

  • Biospecimens

    FluidSerum
    FluidPlasma
    TissueBlood Vessel
    FluidBlood
  • Preservation Types

    Frozen
  • Diagnoses

    Cardiovascular Disease
    Coronary Artery Disease
    Other diagnoses
    Normal
  • Platforms

    ProteinImmunoassay
    ProteinSize-exclusion chromatography
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Abdominal aortic aneurysm
    Acute coronary syndrome
    Atherosclerosis
    Cerebrovascular attack
    Haemodialysis patient
    Infection
    Multiple trauma
    Vascular surgery
    PreaquisitionOther drugs
    Intravenous bivalirudin
    Intravenous low molecular weight heparin
    Intravenous unfractionated heparin
    Subcutaneous low molecular weight heparin
    PreaquisitionPatient gender
    Female
    Male
    Biospecimen AcquisitionBiospecimen location
    Plaque tissue
    Plasma
    Serum
    Biospecimen AcquisitionTime of biospecimen collection
    1 h prior to administration
    10 min post administration
    12 h post administration
    15 min post administration
    2 h post administration
    30 min post administration
    4 h post administration
    40 min post administration
    5 min post administration
    6 h post administration
    60 min post administration
    70 min post administration
    Time 0
    Biospecimen Aliquots and ComponentsBlood and blood products
    Plasma
    Serum